CME Activities

Online Programs

Apr
14
Tue
Applying Evidence-Based Therapy Through Oncology Nursing That Maximizes HER2-Targeted Efficacy While Enhancing Tolerability
Apr 14 2020 @ 8:00 am – Apr 14 2023 @ 9:00 am


Applying Evidence-Based Therapy Through Oncology Nursing That Maximizes HER2-Targeted Efficacy While Enhancing Tolerability

VIEW ACTIVITY

FACULTY

Vamsidhar Velcheti, MD, FACP, FCCP
Director of Thoracic Medical Oncology
NYU Langone
Professor of Medicine
Perlmutter Cancer Center
New York, NY

Evelyn Robles-Rodríguez, DNP, APN, AOCN
Director, Outreach, Prevention and Survivorship
MD Anderson Cancer Center at Cooper
Camden, NJ

PROGRAM OVERVIEW

Oncology nurses are in an inherently valuable position to be in the frontline for treatment of HER2-positive solid tumors. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience. For additional resources, please visit www.oncologynurse-ce.com.

TARGET AUDIENCE

The primary audience for this educational activity is oncology nurses. A secondary target audience consists of other primary care HCPs (eg, nurse practitioners, pharmacists, physician assistant) involved in the management of patients with gastric cancer, breast cancer, and other HER2-positive advanced tumors.

LEARNING OBJECTIVES

  • Evaluate the role that human epidermal growth factor receptor plays in the tumorigenesis and prognosis of patients with HER2-positive solid tumors.
  • Summarize the efficacy and safety data of both HER2-targeted ADCs and kinase inhibitors in the 2nd line treatment of patients with HER2-positive solid tumors
  • Discuss best practices for the safe intravenous administration of ADC therapy and monitoring for adverse events in patients with HER2-positive advanced disease beyond the first-line
  • Appreciate the essential role the oncology nurse plays in patient education and management of treatment-related adverse events of HER2-directed therapy

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in caring for patients with gastric cancer, breast cancer, and other HER2-positive advanced tumors.
CNE Credits: 1.5 ANCC Contact Hours.

ONCC STATEMENT

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Vamsidhar Velcheti MD, FACP, FCCP discloses that he has received consulting fees from BMS, Merck, AstraZeneca, Amgen, Foundation Medicine, and Regeneron.

Evelyn Robles-Rodríguez, DNP, APN, AOCN discloses that she has received research grants from Genentech and Pfizer.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Debra Gordon, Medical Director of Med Learning Group, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
  • Aimee Meissner, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASE DATE: June 29, 2022

EXPIRATION DATE: June 29, 2023

VIEW ACTIVITY

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Apr
29
Wed
A Nurses’ Perspective: Oral Therapies in Breast Cancer: Considerations for Enhanced Adherence in the Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer
Apr 29 2020 @ 8:00 am – Apr 29 2023 @ 9:00 am


A Nurses’ Perspective: Oral Therapies in Breast Cancer: Considerations for Enhanced Adherence in the Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer

VIEW ACTIVITY

FACULTY

Sramila Aithal, MD
Breast Oncologist/Hematologist
Alliance Cancer Specialists
US Oncology Network
Philadelphia, PA

Evelyn Robles-Rodríguez, DNP, APN, AOCN
Director, Outreach, Prevention and Survivorship
MD Anderson Cancer Center at Cooper
Camden, New Jersey

PROGRAM OVERVIEW

Oncology nurses are in an inherently valuable position to be in the frontline of breast cancer treatment for patients. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience.

TARGET AUDIENCE

This activity is intended for frontline US-based oncology nurses, oncologists, advanced practice clinicians, and pharmacists caring for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

LEARNING OBJECTIVES

  • Evaluate patient education strategies to enhance adherence and persistence to treatment with oral oncolytic therapies in the setting of HR+/HER2- BC
  • Discuss the importance of side effect monitoring, recognition, management, and patient education in enhancing patient quality of life and treatment persistence in HR+/HER2- BC treated with oral oncolytics
  • Optimize nursing strategies for optimal communication, patient care coordination, and multidisciplinary care team collaboration

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in caring for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
CNE Credits: 1.5 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.

ONCC STATEMENT

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Sramila Aithal MD, discloses she is on the on the speakers’ bureau for Pfizer, Seagen, Daichii/Astrazeneca and Merck.

Evelyn Robles-Rodríguez, DNP, APN, AOCN discloses that she has received a research grant from Genentech and Pfizer.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Joan Duer-Hefele, RN, MA, CCRC

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Dave Chatman, Medical Director of Med Learning Group, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
  • Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
  • Aimee Meissner, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASE DATE: April 29, 2022

EXPIRATION DATE: April 29, 2023

VIEW ACTIVITY

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Nov
17
Tue
HER2-Positive/TNBC: Oncology Nurses Quality Improvement Series
Nov 17 2020 @ 3:04 pm – Nov 17 2021 @ 4:04 pm

HER2-Positive/TNBC: Oncology Nurses Quality Improvement Series

VIEW ACTIVITY

PRESENTATION TRACKS

The Roles of Oncology Nurses in Next-generation Approaches to the Management of Advanced HER2-Positive Breast Cancer

FACULTY

Andrea Rodriguez, CRNP, AOCNP
Women’s Cancer Center
Magee-Women’s Cancer Hospital
University of Pittsburgh Medical Center
Pittsburgh, PA

Optimizing Treatment with Immune Checkpoints Inhibitors: The Collaborative Care of Patients with Triple Negative Breast Cancer

FACULTY

Sramila Aithal, MD
Director and Lead, Breast Center of Advanced Oncology
Medical Oncologist and Hematologist
Cancer Treatment Centers of America
Philadelphia, PA

PROGRAM OVERVIEW

This case-based online activity will cover the treatment and management of patients with HER2-positive breast cancer and triple negative breast cancer.


TARGET AUDIENCE

This activity is designed to meet the educational needs of U.S.-based nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians involved in the management of patients with breast cancer (BC). Also, this initiative is designed to meet the educational needs of U.S.-based nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians involved in the treatment of patients with triple negative breast cancer (TNBC).


LEARNING OBJECTIVES – HER-2 Positive

Upon completion of the program, attendees should be able to:

  • Identify the mechanisms underlying resistance to monoclonal antibodies currently approved for first-line treatment of advanced HER2-positive breast cancer
  • Discuss next-generation second-line approaches to the treatment of advanced HER2-positive breast cancer including antibody–drug conjugate technology
  • Describe the mechanisms of action and clinical profiles of approved and emerging antibody–drug conjugates used to treat advanced HER2-positive breast cancer in the second-line setting
  • Review the various roles for oncology nurses in the management of patients with advanced HER2-positive breast cancer who are treated or eligible for treatment with antibody–drug conjugates

LEARNING OBJECTIVES – Triple Negative Breast Cancer

Upon completion of the program, attendees should be able to:

  • Explain the complementary mechanisms found with the combination of chemotherapy and immunotherapy agents in the treatment of TNBC
  • Apply evidence-based data derived from clinical trials to optimize combination regimens for the treatment of patients with metastatic TNBC
  • Describe patient-centered shared decision-making approaches intended to optimize oncology care in patients with TNBC
  • Discuss the roles that oncology nurses can play in the management of patients with metastatic TNBC who are treated or eligible for treatment with immunotherapy

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 2.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the management of patients with BC and/or the treatment of patients with TNBC.
CNE Credits: 2.0 ANCC Contact Hours


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.0 contact hours of continuing nursing education for RNs and APNs.


ONCC STATEMENT

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Andrea Rodriguez, CRNP, AOCNP, has nothing to disclose.

Sramila Aithal, MD is a Speakers’ Bureau member for Pfizer, Novartis, Seattle Genetics and Puma. She was a principal investigator for pharmaceutical initiated clinical trials at CTCA.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete the pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

RELEASE DATE: November 17, 2020

EXPIRATION DATE: November 17, 2021

VIEW ACTIVITY

 


Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

irAEs/HER2-Negative: Oncology Nurses Quality Improvement Series
Nov 17 2020 @ 3:04 pm – Nov 17 2021 @ 4:04 pm

irAEs/HER2-Negative: Oncology Nurses Quality Improvement Series

VIEW ACTIVITY

PRESENTATION TRACKS

Immune Checkpoint inhibitors: The Oncology Nurse’s Role in the Monitoring and Early Intervention of Immune-related Adverse Events

FACULTY

Arjun V. Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

Updates for Oncology Nurses—Optimizing the Paradigm Shift Driven by CKD 4/6 Inhibitors in Metastatic HR-Positive, HER2-Negative Breast Cancer

FACULTY

Sramila Aithal, MD
Director and Lead, Breast Center of Advanced Oncology
Medical Oncologist and Hematologist
Cancer Treatment Centers of America
Philadelphia, PA

PROGRAM OVERVIEW

This case-based online activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy, as well as, the treatment and management of patients with HER2-negative breast cancer.


TARGET AUDIENCE

This initiative is designed to meet the educational needs of oncology nurses involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy. Also, this initiative is designed to meet the educational needs of oncology nurses, medical oncologists, pharmacists, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.


LEARNING OBJECTIVES – irAEs

Upon completion of the program, attendees should be able to:

  • Review the mechanism of action and clinical profiles of available and emerging immunotherapies used alone or in combination across lines of therapy in multiple tumor types
  • Describe the side effects and toxicities associated with available immunotherapeutic options for the treatment of patients with various types of cancer and strategies to manage them in clinical practice
  • Summarize best practices for the use of biomarker testing in clinical practice to guide treatment making decisions regarding cancer immunotherapies including the potential for response to therapy and the occurrence of irAEs
  • Discuss current recommendations and emerging evidence regarding the use of immunotherapies for patients with cancer during the COVID-19 pandemic including the management of irAEs and the utility of telemedicine
  • Describe the fundamentals of patient-centered SDM approaches and their utility in optimizing patient care in clinical practice

LEARNING OBJECTIVES – HER2-Negative

Upon completion of the program, attendees should be able to:

  • Identify the patient who will benefit from CDK 4/6 inhibitor therapy with consideration of patient and disease characteristics and appropriately time its use in the course of the disease
  • Recognize commonly associated toxicities of CDK4/6 inhibition, and apply strategies for both the monitoring and management of adverse events associated with their use in patients with metastatic breast cancer
  • Utilize methodologies to activate all members of the healthcare team, encourage collaboration, and incorporate shared-decision-making and survivorship tools to assist in optimizing patient outcomes and management of adverse events
  • Review the various roles for oncology nurses in the management of patients with breast cancer

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 2.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy and/or hormone receptor-positive, HER2-negative metastatic breast cancer.
CNE Credits: 2.0 ANCC Contact Hours.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.0 contact hours of continuing nursing education for RNs and APNs.


ONCC STATEMENT

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Arjun V. Balar, MD, has received consultant fees from Merck, Genentech, AstraZeneca, Pfizer, and Seattle Genetics; and received fees for non-CME/CE services received directly from a commercial interest or its agent from Merck, Genentech, and AstraZeneca.

Sramila Aithal, MD is a Speakers’ Bureau member for Pfizer, Novartis, Seattle Genetics and Puma. She was a principal investigator for pharmaceutical initiated clinical trials at CTCA.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

 


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the posttest and online evaluation form.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

RELEASE DATE: November 17, 2020

EXPIRATION DATE: November 17, 2021

 

VIEW ACTIVITY

 


Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These CME activities are planned and produced in accordance with the ACCME Essentials.